非小细胞肺癌ctDNA监测耐药相关伴随基因研究进展OACSTPCD
Research progress on dynamic monitoring of ctDNA and drug resistance related concomitant mutations in non-small cell lung cancer
肺癌靶向治疗显著延长了患者的生存时间,已成为晚期驱动基因阳性非小细胞肺癌患者标准治疗.但肺癌患者的基因状态是动态变化的,通过动态监测基因状态的变化,可早期发现与肺癌疾病进展相关差异基因和伴随基因,从而更加精准地实现对肺癌靶向治疗全程管理的全方位掌握.根据精确基因检测指导下的靶向药应用,有助于为患者提供更切实有效、更长期稳定的个体化靶向治疗指导,达到最佳临床获益.
Owing to significantly prolonged survival,targeted therapy has become standardized recommendation for ad-vanced non-small cell lung cancer patients with mutated driver genes.However,the genetic status of lung cancer patients is dynam-ic.By dynamically monitoring the evolution of genes status,differential genes and concomitant genes related to progressive disease could be confirmed early,so as to achieve a more accurate and comprehensive insight of the whole process management of targeted therapy for lung cancer patients.Under the guidance of accurate genetic testing results,it is helpful to provide patients with more effective,long-term,and stable individualized targeted therapy.
薛崇祥;张旭;鲁星妤;崔慧娟
北京中医药大学,北京 100029||中日友好医院/国家呼吸医学中心/国家中西医结合医学中心 中西医结合肿瘤内科,北京 100029北京中医药大学,北京 100029中日友好医院/国家呼吸医学中心/国家中西医结合医学中心 中西医结合肿瘤内科,北京 100029
临床医学
非小细胞肺癌ctDNA靶向治疗伴随突变研究进展
Non-small cell lung cancerCtDNATargeted therapyConcomitant mutationsResearch progress
《海南医学院学报》 2024 (004)
基于PLA2G4A基因的IL-6/STAT3信号通路调控的“止痒平肤液”对靶向药相关皮疹疗效的分子机制研究
304-308 / 5
National Natural Science Foundation of China(81873396);Capital Health Development Research Project(2018-2-4065);Project of China-Japan Friendship Hospital(2018-HX-26)国家自然科学基金(81873396);首都卫生发展科研专项(2018-2-4065);中日友好医院课题(2018-HX-26)
评论